Canada: Court Upholds Board’s Decision Refusing Trademark For Lack Of Distinctiveness (Intellectual Property Weekly Abstracts Bulletin: Week Of January 19, 2015)

Last Updated: January 22 2015
Most Read Contributor in Canada, September 2016

Edited by Chantal Saunders and Beverley Moore , Adrian Howard and Ryan Steeves

Trademarks Decisions

Court Upholds Board's Decision Refusing Trademark for Lack of Distinctiveness

Philip Morris Products SA v. Imperial Tobacco Canada Limited, 2014 FC 1237

This was an appeal from a decision of the Registrar of Trademarks' decision to decline Philip Morris' application to register the proposed trademark "FLIP-TOP". The Court dismissed the appeal.

The issue on appeal was whether the Board erred in finding that the proposed mark could not be registered because it was not distinctive. The Federal Court refused to consider the issue of whether the proposed mark was clearly descriptive, because the Board had considered the issue but had expressly refused to make a finding.

Both parties filed new evidence, however the Court held it would not have materially affected the Board's decision. Thus, the Court assessed the decision using the reasonableness standard. The Court held it was open to the Board to conclude that the term "FLIP TOP" in association with tobacco products was not distinctive. Thus, it was reasonable, and the Federal Court dismissed the appeal.

Other Decisions of Interest

Court Finds Claims Do Not Cover Method of Medical Treatment, Orders that they Issue

Abbvie Biotechnology Ltd. v. Canada (AG), 2014 FC 1251

In this decision, Abbvie brought a judicial review of a decision of the Commissioner of Patents refusing to issue its patent. The issue was whether the claims were directed to a method of medical treatment. The Court disagreed, held that the claims were patentable, and directed that they be allowed.

The Court considered the standard of review and held that it is correctness. The issue is a pure question of law relating to the statutory limits of patentable subject matter. There are no facts in dispute. The only issue is the Commissioner's interpretation of statutory subject matter and, more specifically, the scope of the prohibition on methods of medical treatment.

The Court held that the skill and judgment of the physician is exercised when a decision is made as to whether or not to use the claimed invention in the treatment of a patient. Furthermore, "just because the claims involve a fixed dosage and schedule does not mean that they are automatically patentable, nor does it mean that they constitute unpatentable subject matter." (para. 113) The jurisprudence is consistent that when the claim is directed to the exercise of professional skill or judgment, it is not patentable. In this case, the claim was to a vendible product. The skill and judgment relates to whether or not to prescribe that product. Thus, the claim was patentable.

The Court then held that the Commissioner had already found the claims to be not anticipated and not obvious. Only the issue of patentable subject matter was to be resolved. Thus, the Court held there is nothing more to re-examine and the claims should issue.

Court Refused to Grant Protective Order Covering NOA

Takeda Canada Inc. v. Mylan Pharmaceuticals ULC, 2014 FC 1076

In the context of a proceeding brought pursuant to the NOC Regulations, Mylan sought a confidentiality that would allow it to designate portions of its Notice of Allegation (NOA) as confidential and shield it from public disclosure.

The Court refused to grant a confidentiality order covering portions of the NOA, as Mylan did not treat the information as confidential at all material times. It held that Mylan had voluntarily sent it to Takeda with no reasonable expectation of it being kept confidential. Furthermore the Court refused to allow Mylan to mark as confidential a fact affidavit attesting to why the NOA should be confidential. The Court held that Mylan had no real expectation that the affidavit would be kept confidential, and furthermore, it did not contain any confidential information.

The Court also considered and rejected Mylan's argument that it being the first to enter a generic market is sufficiently important a commercial interest to justify the confidentiality order. The Court held that other generic companies are part of the "public", and they have an interest in this material.

Minister's Decision to Grant NOA to Generic Company Set Aside, as the Generic did not Comply with the NOC Regulations

Pfizer Canada Inc. v. Teva Canada Limited, 2014 FC 1243

In this proceeding, Pfizer sought to judicially review the Minister of Health's decision to grant Teva a NOC for exemestane. A company called GMP filed an ANDS for exemestane. However, it sent a NOA to Pfizer for atorvastatin. Health Canada issued a NOC to GMP for exemestane. Teva then filed an administrative ANDS seeking approval to market exemestane, and was granted a NOC.

Pfizer started a proceeding seeking to quash the NOC issued to Teva. GMP sent a letter to Health Canada indicating that it had sent the wrong NOA to Pfizer. Health Canada informed GMP and Teva that the NOCs would be rescinded and Pfizer discontinued its judicial review.

GMP sent a NOA to Pfizer with respect to exemestane. Pfizer did not start a proceeding, as GMP does not sell products in Canada. GMP was issued a new NOC. Teva was also issued a new NOC. Health Canada's records indicate that Teva filed an administrative ANDS, based on a licensing agreement with GMP and Health Canada determined that Pfizer's AROMASIN exemestane product was the reference product for Teva's exemestane product. Pfizer started the within judicial review.

The Court held that the Minister's decision must be reviewed on the basis of correctness. The Court held that the NOC Regulations exist not only to allow generic companies to early work patented medicines, but also to balance these interests with those of the patentee in obtaining protection for inventions that are legitimately patented. The Court held that Teva made exactly the sort of comparison contemplated by the NOC Regulations. Once the purpose of the NOC Regulations was understood, it supports the conclusion that Teva must comply with them. Thus, the application was granted and the Minister's decision granting Teva a NOC was set aside.

Other Industry News

Health Canada has published a Draft Guidance Document - Tamper-Resistant Formulations of Opioid Drug Product Submissions. The Consultation is open until March 7, 2015.

Health Canada has released drafts of Part I: Health Professional Information and Part II: Scientific Information - Guidance Document: Product Monograph. The Consultation is open until March 4, 2015.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.